Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288064 | 0.87 | KDM4E (0.38) | MEN1MAPTKMT2A | |
| SCHEMBL3869210 | 0.81 | PTPRC (0.33) | LMNAMAPTTSHRNPC1RAB9A | |
| SCHEMBL862821 | 0.80 | COMT (0.40) | LMNAMEN1USP2GAAMAPT | |
| SCHEMBL20806202 | 0.79 | COMT (0.39) | LMNAMEN1USP2GAAMAPT | |
| SCHEMBL17249781 | 0.78 | PDK2 (0.37) | — | |
| SCHEMBL10210065 | 0.77 | MAPT (0.39) | LMNAMEN1USP2MAPTTSHR | |
| SCHEMBL32680945 | 0.77 | MAPT (0.37) | LMNAGAAMAPTNPC1RAB9A | |
| SCHEMBL29637958 | 0.77 | MAPT (0.46) | LMNAMEN1USP2GAAMAPT | |
| SCHEMBL711946 | 0.76 | ALDH1A1 (0.41) | MEN1MAPTKMT2A | |
| SCHEMBL31668874 | 0.74 | APP (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482490-B2 | Amine compound having fluorene group as framework, process for producing the amine compound, and use of the amine compound | TOSOH CORPORATION (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20080194878-A1 | Amine Compound Having Fluorene Group as Framework, Process for Producing the Amine Compound, and Use of the Amine Compound | TOSOH CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1752440-A1 | AMINE COMPOUND HAVING FLUORENE GROUP AS FRAMEWORK, PROCESS FOR PRODUCING THE AMINE COMPOUND, AND USE OF THE AMINE COMPOUND | Tosoh Corporation (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194878-A1 | Amine Compound Having Fluorene Group as Framework, Process for Producing the Amine Compound, and Use of the Amine Compound | TAAR1, SLC18A1, ADRB2 | LMNA 3580/4885MEN1 1708/4885USP2 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.